All In Biotech

Drug Trial Radar · NCT05490030

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants

Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 6, 2025

Primary completion

Jun 26, 2025

Study completion Jun 26, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
Collaborators
Pharmaceutical Research Associates
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155. The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.

Conditions

  • Hepatic Impairment

Interventions

  • TNO155Drug

    Single oral dose of TNO155 on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-versus-time curve (AUC) from time zero to the last measurable plasma concentration (AUClast) of TNO155Time frame: Up to 240 hours post single dose
  2. AUC from time zero to time "t" (AUC0-t) of TNO155Time frame: Up to 240 hours post single dose
  3. AUC from time zero to infinity (AUCinf) of TNO155Time frame: Up to 240 hours post single dose
  4. Maximum (peak) observed plasma concentration (Cmax) of TNO155Time frame: Up to 240 hours post single dose
  5. Time to reach maximum observed plasma concentration (Tmax) of TNO155Time frame: Up to 240 hours post single dose
  6. Elimination half-life (T1/2) of TNO155Time frame: Up to 240 hours post single dose
  7. Sampling time of the last measurable plasma concentration (Tlast) of TNO155Time frame: Up to 240 hours post single dose
  8. Apparent plasma clearance (CL/F) of TNO155Time frame: Up to 240 hours post single dose
  9. Apparent volume of distribution during terminal phase (Vz/F) of TNO155Time frame: Up to 240 hours post single dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.